CTIX Cellceutix Corporation featured news, full reports, and detailed charts
Cellceutix Corporation (CTIX/CTIX.OB) Wrap Up:
Cellceutix Corporation operates as a development stage biopharmaceutical company in the United States. It has the rights to six different pharmaceutical compound candidates that are designed for treatment of diseases. The company’s lead product candidate, Kevetrin, is used for the treatment of head and neck cancers. Its portfolio of product candidates in pre-clinical development includes two anti-cancer agents targeting various tumors, including rheumatoid arthritis and osteo-arthritis/asthma; and a small molecule with the potential for indications of neurological disorders for the treatment of multiple sclerosis, lou gherig disease, and parkinson's disease. Cellceutix Corporation was former...Cellceutix Corporation (CTIX:OTC Bulletin Board Market)
Snapshot of Cellceutix Corporation (CTIX)
|
OPEN
--
|
PREVIOUS CLOSE
$0.50
|
|
|
DAY HIGH
--
|
DAY LOW
--
|
|
|
52 WEEK HIGH
10/16/09 - $1.01
|
52 WEEK LOW
11/25/08 - $0.20
|
|
|
MARKET CAP
45.9M
|
AVERAGE VOLUME 3 mo
5.2K
|
|
|
DILUTED EPS TTM
$-0.02
|
SHARES OUTSTANDING
91.9M
|
|
|
CTIX Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
CTIX Top Compensated Officers
Executives, Board Directors
Key developments for Cellceutix Corporation (CTIX)
Cellceutix Corporation announced that it presented a poster. The company's poster describes in vitro and in vivo research on its lead compound, Kevetrin(TM), which is being developed for drug resistant cancers. In the in vivo studies, Kevetrin was found to significantly delay tumor growth in two multi-drug resistant lung cancer cell lines. In two experiments with the NCI-H1975 cell line, Kevetrin showed an average tumor growth delay of 149% compared to controls, while paclitaxel delayed tumor growth an average of 72%. The delay in Kevetrin treated animals was significantly greater than in the animals treated with paclitaxel (p<0.01). In two experiments with the A549 cell line, Kevetrin showed an average tumor growth delay of 72% compared to controls while paclitaxel showed an average tumor growth delay of 6%. Again, the delay in Kevetrin treated animals was significantly greater than in the animals treated with paclitaxel (><0.01). In the in vitro studies, the cytotoxicity of Kevetrin was found to be less than that of paclitaxel or cisplatin and Kevetrin was found to inhibit specific AKT, p38 MAP kinase activity and pmTOR kinase activity. Since Kevetrin had greater anti-tumor activity compared to paclitaxel despite being less cytotoxic, this suggests that Kevetrin may be targeting specific components of the signal transduction pathway, such as AKT, p38 MAP kinase, or the pmTOR kinase activity, rather than acting primarily as a cytotoxic agent>
Cellceutix Corporation announced earnings results for the year ended June 30, 2009. Net loss for the fiscal year was $1.48 million, up from $510,193 for the previous fiscal year. Loss per share for the fiscal year were $0.02, up from $0.01 for the previous fiscal year.
Cellceutix Corporation, in a filing with the Securities and Exchange Commission said that, the company will raise additional funds. The company said, “As of June 30, 2009 the Company had a cash balance of $140,380. The Company will need to raise substantial funds in order to execute its product development plan. Based upon our expected rate of expenditures, we currently do not have sufficient cash reserves to meet all of our anticipated obligations through our fiscal year end of June 30, 2010. The Company may seek to raise capital through an offering of our common stock or other securities of the Company. However, there can be no assurance that we will be successful in securing the capital we require or that we may obtain financing on terms and conditions that are acceptable to the Company.”
Stock Quotes
| Recently Viewed | |||
| CTIX | $0.50 USD | 0.00 | |
|---|---|---|---|
Market data is delayed at least 20 minutes.
CTIX Competitors
| Company | Last | Change |
| AstraZeneca | 2,695 GBX | -11.50 |
| Sanofi - Aventis | €50.37 EUR | +0.07 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | CTIX | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
CTIX |
||
CTIX transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
Companies Toolbox
content errors
SEARCH FOR JOBS
Post a Job- Medical Sales Account ManagerPainesville, OH-Avery Dennison
- Houston, TX-Halliburton
- New York, NY-Duff & Phelps
- Los Angeles, CA-CB Richard Ellis
Jobs by SimplyHired
For Cellceutix Corporation (CTIX) Snapshot
Submitting this data update / error report instantly puts the correct information in the hands of our researcher, who will investigate your report and, if necessary, make the changes to the company profile. Be sure to fill out the form completely.
Please indicate in which section the error appears. Section headers are in light gray type at the top of each CIC page module.
Please indicate which data is in error.
Please provide your name and email address in case our researchers need to get in touch with you as they investigate the error.
Describe why you feel the data point is incorrect and indicate sources our researchers should check when they investigate the error.
More Recent News About Cellceutix Corporation
More news for CTIX
Cellceutix Signs Agreement for Kevetrin(TM) Safety Studies With Toxikon Corporation
Company Advances Kevetrin Toward Human Studies, Targeting Resistant Cancers Last Hurdle Before IND Filing BEVERLY, Mass., Nov. 2, 2009 (GLOBE NEWSWIRE) -- Cellceutix Corporation (OTCBB:CTIX - News), a bio-pharmaceutical company that develops small molecules to treat cancer and inflammatory disease, today announced that is has concluded an agreement with Toxikon Corporation of Bedford, Massachusetts, to conduct the remaining preclinical studies required for an Investigational New Drug (IND) filing for its cancer drug Kevetrin(TM). The terms of the agreement were not disclosed. The studies covered by the agreement are designed to confirm that Kevetrin meets FDA safety requirements for studies in humans. "We believe we've found an excellent, globally recognized partner in Toxikon," said George Evans, CEO of Cellceutix. "This is a big step for Cellceutix and represents our last hurdle before asking the U.S. FDA for permission to conduct Phase 1 human studies with Kevetrin, our lead drug candidate." Kevetrin is being developed to treat drug resistant cancers. The Company has recently reported that Kevetrin showed greater tumor shrinkage than standard therapies in animal models of resistant lung cancer and resistant breast cancer. Kevetrin recently received national attention when the American Association for Cancer Research (AACR), chose to feature an abstract of animal model experiments with Kevetrin in multi-drug resistant lung cancer cell ...Click here to read the whole Article (external link)
Attacking Cancer With Specific Anti-Tumor Pathways
BEVERLY, Mass., Oct. 19, 2009 (GLOBE NEWSWIRE) -- Cellceutix Corporation (OTCBB:CTIX - News) today announced that data recently presented by the Company at the American Association for Cancer Research (AACR) along with other data developed by the Company indicate that Kevetrin is selectively targeting very specific anti-tumor pathways, such as AKT and p38 MAP kinase. The data presented at the AACR showed that Kevetrin was less cytotoxic than paclitaxel, cisplatin and 5FU while having better anti-tumor activity in two multi-drug resistant lung cancer cell lines. This indicates that Kevetrin is not acting primarily as a cytotoxic agent but may be targeting specific components of the signal transduction pathway, such as AKT and p38 MAP kinase. The Company is continuing to explore other potential targets. Other data developed by the Company indicate that Kevetrin has potent anti-tumor activity in one cell line (MDA-MB--231) despite only partially inhibiting AKT in that cell line. AKT and p38 MAP kinase are important targets in fighting cancers. Kinases are molecules that play a role in many aspects of cell function. The activity of AKT, a protein kinase, is increased in many tumors thereby increasing the survival of cancer cells that would otherwise die. p38MAP is another protein kinase important for tumor cell survival. On October 9, 2009, an abstract describing animal model experiments with Kevetrin in multi-drug resistant lung cancer cell lines was one of four selected in a press release by The American A...Click here to read the whole Article (external link)
CELLCEUTIX CORP Financials
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...Click here to read the whole Article (external link)
Cellceutix Poster Presented At American Association for Cancer Research; Dr. Menon Selected for Expert Panel
Kevetrin(TM) Shows Excellent Activity in Animal Models of Drug Resistant Lung Cancer With Less Cytotoxicity Than Paclitaxel Cellceutix of Beverly, MA, to Pursue Development for Drug-Resistant Lung Cancer BEVERLY, Mass., Oct. 13, 2009 (GLOBE NEWSWIRE) -- Cellceutix Corporation (OTCBB:CTIX - News) today announced that it presented a poster and its Chief Scientific Officer, Dr. Krishna Menon, was one of only four individuals selected to participate in an expert panel discussion of the abstract at the American Association for Cancer Research (AACR) meeting "Frontiers in Basic Cancer Research" in Boston, MA on October 10, 2009. The Company's poster describes in vitro and in vivo research on its lead compound, Kevetrin(TM), which is being developed for drug resistant cancers. The three day AACR meeting featured presentations on the latest advances in basic cancer research from around the world. The AACR issued a press release on October 10, 2009 which featured the abstract submitted by Cellceutix http://www.aacr.org/home/public--media/aacr-press-releases.aspx?d=1571 In the in vivo studies, Kevetrin was found t...Click here to read the whole Article (external link)
CELLCEUTIX CORP Files SEC form 10-K, Annual Report
ITEM 7. MANAGEMENT'S DISCUSSION AND FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and plan of operations should read in conjunction with the financial statements and the notes to those statements included in this Form 10-K. This discussion includes forward-looking statements that involve risk and uncertainties. As a result of many factors, such as those set forth under "Risk Factors," actual results may differ materially from those anticipated in these forward-looking statements. Acquisition and Reorganization On December 6, 2007, the Acquisition of Cellceutix Pharma, Inc. was completed, and the business of Cellceutix Pharma, Inc. was adopted as our business. As such, the following Management Discussion is focused on the current and historical operations of Cellceutix Pharma, Inc. and excludes the prior operations of EconoShare, Inc.. Management's Plan of Operation As a result of the Exchange with Cellceutix Pharma, Inc., we are an early stage developmental biopharmaceutical company. We have no product sales to date and we will not receive any product revenue until we receive approval from the FDA or equivalent foreign regulatory bodies to begin selling our pharmaceutical candidates. Developing pharmaceutical products, however, is a lengthy and very expensive process. Assuming we do not encounter any unforeseen safety issues during the course of developing our product candidates, we do not expect to complete the development of a product candidate for several years, if ever. In August and October 2007, we acquired exclusive rights to a total of six (6) pharmaceutical compound candidates that are designed for treatment of diseases which may be either existing or diseases identified in the future. In July, 2009 we acquired the rights to an additional compound. The Company will initially spend most of its efforts and resources on its anti-cancer compound, Kevetrin, for the treatment of certain cancers. Kevetr...Click here to read the whole Article (external link)
AXcess News: Breast Cancer Awareness Draws Investors Too
HOUSTON, TX--(Marketwire - 10/05/09) - October is breast cancer awareness month with many supporters touting pink ribbons, but in health stocks investors are watching the market closely for news of new drugs in various stages of testing. Recently, Cellceutix (OTC.BB:CTIX - News) announced its pharmaceutical compound Kevetrin reduced tumor volume by 72%, giving new hope for breast cancer patients. Cellceutix's Kevetrin compound has shown itself effective against drug-resistant cancer cells which the Company's Chief Scientific Officer Dr. Krishna Menon says were "very consistent" results compared with earlier tests conducted in July. In its late September announcement, the Beverly, Mass.-based Company said that laboratory tests on mice implanted with drug-resistant human cancer cells showed that tumor volume was reduced by 72% while growth was delayed by more than 52% when compared to those mice treated with paclitaxel (Taxol) or with cisplatin."These results are very consistent with the results in multi-drug resistant lung cancer cell lines that we announced in July," said Dr. Menon.Breast cancer is the second leading cause of cancer deaths in women today with nearly one-in-three women diagnosed dying from the deadly disease, a fact that Dr. Menon and his colleagues are all too aware of. In a telephone interview late Monday afternoon, Cellceutix CFO Leo Ehrlich said the Company was "moving as quickly as is possible to begin FDA testing of its Kevetrin compound on humans," though he stopped short of giving details not ...Click here to read the whole Article (external link)
Cellceutix Compound Shows Significant Effect On Psoriasis
BEVERLY, Mass., Oct. 5, 2009 (GLOBE NEWSWIRE) -- Cellceutix Corporation (OTCBB:CTIX - News) today announced that it has successfully completed a study with its proprietary compound, KM-133, in a human xenograft animal model of psoriasis. The study showed that KM-133 reduced psoriasis more than controls (p<0.01). The higher of two doses of KM-133 reduced psoriasis more than methotrexate (p<0.01). Psoriasis did not recur with KM-133 during the entire course of the experiment, whereas psoriasis reoccurred in the group of animals treated with methotrexate after an average of 61 days. The study also looked at histological indications of psoriasis as well as three bio-markers, PRINS, IL-20 and 12-R lipoxygenase, and found that KM-133 had significant effects on all these parameters. Weight losses for the KM-133 treated animals were within acceptable limits. "Those suffering from psoriasis clearly know the urgent need for new treatments. In order to increase the predictive ability of the study, we designed an animal model with human psoriatic tissue to simulate psoriasis in humans. These results clearly show that the higher dose of KM-133 had a superior effect in psoriasis when compared to methotrexate, a standard treatment," said Dr. Krishna Menon, Chief Scientific Officer of Cellceutix. In this study, four groups of ten mice were treated with a single dose per day of KM-133 (10 mg/kg), 2 doses of KM-133 (10 mg/kg x 2) per day, methotrexate (7.5 mg/kg) or acted as controls. The mice were irradiated and th...Click here to read the whole Article (external link)